Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 36

1.

Mast cell activation syndrome: High frequency of skin manifestations and anaphylactic shock.

Casassa EA, Mailhol C, Tournier E, Laurent C, Degboe Y, Eischen M, Kirsten N, Moreau J, Evrard SM, Mansat-De Mas V, Lamant L, Dubreuil P, Apoil PA, Hermine O, Paul C, Bulai Livideanu C.

Allergol Int. 2018 Aug 7. pii: S1323-8930(18)30086-8. doi: 10.1016/j.alit.2018.07.003. [Epub ahead of print] No abstract available.

2.

Oncogenic FLT3-ITD supports autophagy via ATF4 in acute myeloid leukemia.

Heydt Q, Larrue C, Saland E, Bertoli S, Sarry JE, Besson A, Manenti S, Joffre C, Mansat-De Mas V.

Oncogene. 2018 Feb 8;37(6):787-797. doi: 10.1038/onc.2017.376. Epub 2017 Oct 23.

3.

CDC25A governs proliferation and differentiation of FLT3-ITD acute myeloid leukemia.

Bertoli S, Boutzen H, David L, Larrue C, Vergez F, Fernandez-Vidal A, Yuan L, Hospital MA, Tamburini J, Demur C, Delabesse E, Saland E, Sarry JE, Galcera MO, Mansat-De Mas V, Didier C, Dozier C, Récher C, Manenti S.

Oncotarget. 2015 Nov 10;6(35):38061-78. doi: 10.18632/oncotarget.5706.

4.

Antileukemic Activity of 2-Deoxy-d-Glucose through Inhibition of N-Linked Glycosylation in Acute Myeloid Leukemia with FLT3-ITD or c-KIT Mutations.

Larrue C, Saland E, Vergez F, Serhan N, Delabesse E, Mansat-De Mas V, Hospital MA, Tamburini J, Manenti S, Sarry JE, Récher C.

Mol Cancer Ther. 2015 Oct;14(10):2364-73. doi: 10.1158/1535-7163.MCT-15-0163. Epub 2015 Jul 23.

5.

Role of ASXL1 and TP53 mutations in the molecular classification and prognosis of acute myeloid leukemias with myelodysplasia-related changes.

Devillier R, Mansat-De Mas V, Gelsi-Boyer V, Demur C, Murati A, Corre J, Prebet T, Bertoli S, Brecqueville M, Arnoulet C, Recher C, Vey N, Mozziconacci MJ, Delabesse E, Birnbaum D.

Oncotarget. 2015 Apr 10;6(10):8388-96.

6.

Prognostic impact of JAK2V617F mutation in myelodysplatic syndromes: A matched case control study.

de Renzis B, Mansat-De Mas V, Wattel E, Beyne-Rauzy O, Knoops L, Cabrespine A, Azgui Z, Ades L, Kiladjian JJ, Fenaux P; Groupe Francophone des Myelodysplasies (GFM), French Intergroup of Myeloproliferative disorders (FIM).

Leuk Res Rep. 2013 Aug 30;2(2):64-6. doi: 10.1016/j.lrr.2013.06.003. eCollection 2013.

7.

Hemophagocytic syndrome in patients with acute myeloid leukemia undergoing intensive chemotherapy.

Delavigne K, Bérard E, Bertoli S, Corre J, Duchayne E, Demur C, Mansat-De Mas V, Borel C, Picard M, Alvarez M, Sarry A, Huguet F, Récher C.

Haematologica. 2014 Mar;99(3):474-80. doi: 10.3324/haematol.2013.097394. Epub 2013 Oct 18.

8.

CXXC5 (retinoid-inducible nuclear factor, RINF) is a potential therapeutic target in high-risk human acute myeloid leukemia.

Astori A, Fredly H, Aloysius TA, Bullinger L, Mansat-De Mas V, de la Grange P, Delhommeau F, Hagen KM, Récher C, Dusanter-Fourt I, Knappskog S, Lillehaug JR, Pendino F, Bruserud Ø.

Oncotarget. 2013 Sep;4(9):1438-48.

9.

Pim kinases phosphorylate Chk1 and regulate its functions in acute myeloid leukemia.

Yuan LL, Green AS, Bertoli S, Grimal F, Mansat-De Mas V, Dozier C, Tamburini J, Récher C, Didier C, Manenti S.

Leukemia. 2014 Feb;28(2):293-301. doi: 10.1038/leu.2013.168. Epub 2013 Jun 10.

PMID:
23748345
10.

Time from diagnosis to intensive chemotherapy initiation does not adversely impact the outcome of patients with acute myeloid leukemia.

Bertoli S, Bérard E, Huguet F, Huynh A, Tavitian S, Vergez F, Dobbelstein S, Dastugue N, Mansat-De Mas V, Delabesse E, Duchayne E, Demur C, Sarry A, Lauwers-Cances V, Laurent G, Attal M, Récher C.

Blood. 2013 Apr 4;121(14):2618-26. doi: 10.1182/blood-2012-09-454553. Epub 2013 Jan 30.

11.

High frequency of GATA2 mutations in patients with mild chronic neutropenia evolving to MonoMac syndrome, myelodysplasia, and acute myeloid leukemia.

Pasquet M, Bellanné-Chantelot C, Tavitian S, Prade N, Beaupain B, Larochelle O, Petit A, Rohrlich P, Ferrand C, Van Den Neste E, Poirel HA, Lamy T, Ouachée-Chardin M, Mansat-De Mas V, Corre J, Récher C, Plat G, Bachelerie F, Donadieu J, Delabesse E.

Blood. 2013 Jan 31;121(5):822-9. doi: 10.1182/blood-2012-08-447367. Epub 2012 Dec 6.

12.

The short form of RON is expressed in acute myeloid leukemia and sensitizes leukemic cells to cMET inhibitors.

Fialin C, Larrue C, Vergez F, Sarry JE, Bertoli S, Mansat-De Mas V, Demur C, Delabesse E, Payrastre B, Manenti S, Roche S, Récher C.

Leukemia. 2013 Feb;27(2):325-35. doi: 10.1038/leu.2012.240. Epub 2012 Aug 20.

PMID:
22902361
13.

Focal adhesion kinase splice variants maintain primitive acute myeloid leukemia cells through altered Wnt signaling.

Despeaux M, Chicanne G, Rouer E, De Toni-Costes F, Bertrand J, Mansat-De Mas V, Vergnolle N, Eaves C, Payrastre B, Girault JA, Racaud-Sultan C.

Stem Cells. 2012 Aug;30(8):1597-610. doi: 10.1002/stem.1157.

14.

RET fusion genes are associated with chronic myelomonocytic leukemia and enhance monocytic differentiation.

Ballerini P, Struski S, Cresson C, Prade N, Toujani S, Deswarte C, Dobbelstein S, Petit A, Lapillonne H, Gautier EF, Demur C, Lippert E, Pages P, Mansat-De Mas V, Donadieu J, Huguet F, Dastugue N, Broccardo C, Perot C, Delabesse E.

Leukemia. 2012 Nov;26(11):2384-9. doi: 10.1038/leu.2012.109. Epub 2012 Apr 19.

PMID:
22513837
15.

Do AML patients with DNMT3A exon 23 mutations benefit from idarubicin as compared to daunorubicin? A single center experience.

LaRochelle O, Bertoli S, Vergez F, Sarry JE, Mansat-De Mas V, Dobbelstein S, Dastugue N, Strzelecki AC, Cavelier C, Creancier L, Pillon A, Kruczynski A, Demur C, Sarry A, Huguet F, Huynh A, Récher C, Delabesse E.

Oncotarget. 2011 Nov;2(11):850-61.

16.

The cell cycle regulator CDC25A is a target for JAK2V617F oncogene.

Gautier EF, Picard M, Laurent C, Marty C, Villeval JL, Demur C, Delhommeau F, Hexner E, Giraudier S, Bonnevialle N, Ducommun B, Récher C, Laurent G, Manenti S, Mansat-De Mas V.

Blood. 2012 Feb 2;119(5):1190-9. doi: 10.1182/blood-2011-01-327742. Epub 2011 Nov 7.

17.

Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias.

Itzykson R, Kosmider O, Cluzeau T, Mansat-De Mas V, Dreyfus F, Beyne-Rauzy O, Quesnel B, Vey N, Gelsi-Boyer V, Raynaud S, Preudhomme C, Adès L, Fenaux P, Fontenay M; Groupe Francophone des Myelodysplasies (GFM).

Leukemia. 2011 Jul;25(7):1147-52. doi: 10.1038/leu.2011.71. Epub 2011 Apr 15.

PMID:
21494260
18.

Human acute myelogenous leukemia stem cells are rare and heterogeneous when assayed in NOD/SCID/IL2Rγc-deficient mice.

Sarry JE, Murphy K, Perry R, Sanchez PV, Secreto A, Keefer C, Swider CR, Strzelecki AC, Cavelier C, Récher C, Mansat-De Mas V, Delabesse E, Danet-Desnoyers G, Carroll M.

J Clin Invest. 2011 Jan;121(1):384-95. doi: 10.1172/JCI41495. Epub 2010 Dec 13.

19.

Interlaboratory development and validation of a HRM method applied to the detection of JAK2 exon 12 mutations in polycythemia vera patients.

Ugo V, Tondeur S, Menot ML, Bonnin N, Le Gac G, Tonetti C, Mansat-De Mas V, Lecucq L, Kiladjian JJ, Chomienne C, Dosquet C, Parquet N, Darnige L, Porneuf M, Escoffre-Barbe M, Giraudier S, Delabesse E, Cassinat B; French Intergroup of Myeloproliferative disorders.

PLoS One. 2010 Jan 26;5(1):e8893. doi: 10.1371/journal.pone.0008893.

20.

Constitutive activation of the DNA damage signaling pathway in acute myeloid leukemia with complex karyotype: potential importance for checkpoint targeting therapy.

Cavelier C, Didier C, Prade N, Mansat-De Mas V, Manenti S, Recher C, Demur C, Ducommun B.

Cancer Res. 2009 Nov 15;69(22):8652-61. doi: 10.1158/0008-5472.CAN-09-0939. Epub 2009 Oct 20.

21.

TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs).

Kosmider O, Gelsi-Boyer V, Cheok M, Grabar S, Della-Valle V, Picard F, Viguié F, Quesnel B, Beyne-Rauzy O, Solary E, Vey N, Hunault-Berger M, Fenaux P, Mansat-De Mas V, Delabesse E, Guardiola P, Lacombe C, Vainchenker W, Preudhomme C, Dreyfus F, Bernard OA, Birnbaum D, Fontenay M; Groupe Francophone des Myélodysplasies.

Blood. 2009 Oct 8;114(15):3285-91. doi: 10.1182/blood-2009-04-215814. Epub 2009 Aug 7.

22.

Myeloid cell differentiation arrest by miR-125b-1 in myelodysplastic syndrome and acute myeloid leukemia with the t(2;11)(p21;q23) translocation.

Bousquet M, Quelen C, Rosati R, Mansat-De Mas V, La Starza R, Bastard C, Lippert E, Talmant P, Lafage-Pochitaloff M, Leroux D, Gervais C, Viguié F, Lai JL, Terre C, Beverlo B, Sambani C, Hagemeijer A, Marynen P, Delsol G, Dastugue N, Mecucci C, Brousset P.

J Exp Med. 2008 Oct 27;205(11):2499-506. doi: 10.1084/jem.20080285. Epub 2008 Oct 20.

23.

Cell-surface MMP-9 regulates the invasive capacity of leukemia blast cells with monocytic features.

Paupert J, Mansat-De Mas V, Demur C, Salles B, Muller C.

Cell Cycle. 2008 Apr 15;7(8):1047-53. Epub 2008 Jan 18.

PMID:
18414048
24.

Human telomerase is regulated by erythropoietin and transforming growth factor-beta in human erythroid progenitor cells.

Prade-Houdellier N, Frébet E, Demur C, Gautier EF, Delhommeau F, Bennaceur-Griscelli AL, Gaudin C, Martinel V, Laurent G, Mansat-De Mas V, Beyne-Rauzy O.

Leukemia. 2007 Nov;21(11):2304-10. Epub 2007 Aug 23.

PMID:
17713555
25.

Expression of beta-catenin by acute myeloid leukemia cells predicts enhanced clonogenic capacities and poor prognosis.

Ysebaert L, Chicanne G, Demur C, De Toni F, Prade-Houdellier N, Ruidavets JB, Mansat-De Mas V, Rigal-Huguet F, Laurent G, Payrastre B, Manenti S, Racaud-Sultan C.

Leukemia. 2006 Jul;20(7):1211-6. Epub 2006 May 11.

PMID:
16688229
26.

TNFalpha stimulates NKG2D-mediated lytic activity of acute myeloid leukemic cells.

Guilloton F, de Thonel A, Jean C, Demur C, Mansat-De Mas V, Laurent G, Quillet-Mary A.

Leukemia. 2005 Dec;19(12):2206-14.

PMID:
16239914
27.

Tumor necrosis factor-alpha inhibits hTERT gene expression in human myeloid normal and leukemic cells.

Beyne-Rauzy O, Prade-Houdellier N, Demur C, Recher C, Ayel J, Laurent G, Mansat-De Mas V.

Blood. 2005 Nov 1;106(9):3200-5. Epub 2005 Jul 14.

28.

Tumor necrosis factor alpha induces senescence and chromosomal instability in human leukemic cells.

Beyne-Rauzy O, Recher C, Dastugue N, Demur C, Pottier G, Laurent G, Sabatier L, Mansat-De Mas V.

Oncogene. 2004 Sep 30;23(45):7507-16.

PMID:
15326480
29.

Expression of focal adhesion kinase in acute myeloid leukemia is associated with enhanced blast migration, increased cellularity, and poor prognosis.

Recher C, Ysebaert L, Beyne-Rauzy O, Mansat-De Mas V, Ruidavets JB, Cariven P, Demur C, Payrastre B, Laurent G, Racaud-Sultan C.

Cancer Res. 2004 May 1;64(9):3191-7.

30.

Spontaneous STAT5 activation induces growth factor independence in idiopathic myelofibrosis: possible relationship with FKBP51 overexpression.

Komura E, Chagraoui H, Mansat de Mas V, Blanchet B, de Sepulveda P, Larbret F, Larghero J, Tulliez M, Debili N, Vainchenker W, Giraudier S.

Exp Hematol. 2003 Jul;31(7):622-30.

PMID:
12842707
31.
32.

Protein kinase C-zeta overexpression induces erythroid phenotype in the monocytic leukaemia cell line U937.

Mansat-De Mas V, de Thonel A, Gaulin V, Demur C, Laurent G, Quillet-Mary A.

Br J Haematol. 2002 Aug;118(2):646-53.

PMID:
12139760
33.

Oxidative stress-induced activation of Lyn recruits sphingomyelinase and is requisite for its stimulation by Ara-C.

Bezombes C, Plo I, Mansat-De Mas V, Quillet-Mary A, Nègre-Salvayre A, Laurent G, Jaffrézou JP.

FASEB J. 2001 Jul;15(9):1583-5. No abstract available.

PMID:
11427493
34.

Implication of radical oxygen species in ceramide generation, c-Jun N-terminal kinase activation and apoptosis induced by daunorubicin.

Mansat-de Mas V, Bezombes C, Quillet-Mary A, Bettaïeb A, D'orgeix AD, Laurent G, Jaffrézou JP.

Mol Pharmacol. 1999 Nov;56(5):867-74.

35.

The phosphoinositide 3-kinase/Akt pathway is activated by daunorubicin in human acute myeloid leukemia cell lines.

Plo I, Bettaïeb A, Payrastre B, Mansat-De Mas V, Bordier C, Rousse A, Kowalski-Chauvel A, Laurent G, Lautier D.

FEBS Lett. 1999 Jun 11;452(3):150-4.

36.

Daunorubicin- and mitoxantrone-triggered phosphatidylcholine hydrolysis: implication in drug-induced ceramide generation and apoptosis.

Bettaïeb A, Plo I, Mansat-De Mas V, Quillet-Mary A, Levade T, Laurent G, Jaffrézou JP.

Mol Pharmacol. 1999 Jan;55(1):118-25.

Supplemental Content

Loading ...
Support Center